RESEARCH RANGE OF MEDICINES PARACETAMOL (ACETAMINOPHEN)

Анотація

RESEARCH RANGE OF MEDICINES PARACETAMOL (ACETAMINOPHEN)

I. M. Shvaika, О. V. Tryhubchak, T. A. Hroshovyi

Horbachevsky Ternopil State Medical University

Introduction. Nonsteroidal anti-inflammatory drugs the most commonly are prescribed for the treatment of pain and inflammation in the world. For the informed choice of consumers use of nonsteroidal anti-inflammatory drugs should be considered a rational range. The purpose of this work was to conduct a marketing analysis medicines containing paracetamol.

Research methods. Analysis range drugs with paracetamol has conducted by ATC classification system and data of the State Register medicines inUkraine (as of October 2015). The study was carried out using conventional statistical and market researches.

Results and discussion. According to the unified ATC classification system drugs containing acetaminophen include groups N02B - Other analgesics and antipyretics; M01A - Nonsteroidal anti-inflammatory and antirheumatic drugs; N02A - Opiates; R05D - Antitussive agents excluding combination products containing expectorant; R03D - Other medications for regular use of the obstructive respiratory diseases; A03D - antispasmodic agents in combination with analgesics.

InUkrainethere are registered 260 medicines containing paracetamol. Having reviewed the product portfolio of medicines based on paracetamol can be concluded for kids produced and imported 4% drugs. Generic medicines occupy 60% of the drugs compared to original drugs, representing 40% of drugs. The domestic market favors the implementation of combined drugs containing acetaminophen, which is 199 drugs. Among dosage forms and most accessible is the dominant form of tablets (47%). Among them are agents of 9 effervescent properties 3 - dispersed and only 1-soluble. It should also be noted that dosage forms of lead powder to prepare oral solution (28%).

In the domestic market is dominated by imported drugs paracetamol. Their share is 68%, which is more than double the domestic producers. The distribution of paracetamol drugs by producing countriesUkraineoccupies a leading position, it is 32%. This proportion of all domestic manufacturers, including lead LLC "Pharmaceutical company "Zdorov'ya" - 19%. Second place goes Additional liability" INTERCHEM " - 10%, third - PJSC "Pharmaceutical firm "Darnitsa", which is 9%.

Among the foreign producer countriesIndiais dominat - 25%. Uniting producing countries is occupied next position, their share is 8%. In the domestic market drugs fromSpainare also present - 6% of market share andFrance- 5%. Shares importing countries such as theRussian Federation,Latvia,Estonia,China,Turkeyand others are low, ranging from 0% to 3% of the total shares.

Conclusions: The study found that inUkraine 260 medicines based on paracetamol are registered, only 4% from it are for children. Note that generic drugs account for 60% of the market. The domestic market favors the implementation of combination therapies. The most accessible and dominant dosage forms are tablets (47%) and oral powders (28%). Domestic manufacturers provide 32% range, foreign importers offered drugs mainly fromIndia - 25%,Spain - 6%,France - 5%. This demonstrates the feasibility of reorganization researched segment of the market to support domestic producers.

References

1. Derzhavnyy reyestr likarsʹkykh zasobiv : [Elektronnyy resurs] / httpHYPERLINK "http://www.drlz.kiev.ua/"://HYPERLINK "http://www.drlz.kiev.ua/"wwwHYPERLINK "http://www.drlz.kiev.ua/".HYPERLINK "http://www.drlz.kiev.ua/"drlzHYPERLINK "http://www.drlz.kiev.ua/".HYPERLINK "http://www.drlz.kiev.ua/"kievHYPERLINK "http://www.drlz.kiev.ua/".HYPERLINK "http://www.drlz.kiev.ua/"uaHYPERLINK "http://www.drlz.kiev.ua/"/
2. Bobruk V. P. Marketynhovi doslidzhennya farmatsevtychnoho rynku nesteroyidnykh protyzapalʹnykh likarsʹkykh zasobiv Vinnychyny / V. P. Bobruk, O. D. Blahun // Farmatsevtychnyy chasopys. – 2015. – № 1. – S. 80-84.
3. Korinevsʹka H. M. Marketynhovi doslidzhennya rynku antyhipertenzyvnykh preparativ / H. M. Korinevsʹka, O. V. Trygubchak // Farmatsevtychnyy chasopys. – 2011. – № 3 (19). – S. 94-98.
4. Trygubchak O. V. Analysis of the assortment of antidiabetic drugs at the pharmaceutical market ofUkraine/ O. V. Trygubchak // News of pharmacy. – 2015. – № 3 (83). – S. 51-55.
5. Ravliv Yu. A. Marketynhove doslidzhennya rynku biolohichno aktyvnykh dobavok ta likarsʹkykh zasobiv, shcho mistyatʹ aminokysloty / Yu. A. Ravliv, O. V. Trygubchak, T. A. Hroshovyy // Farmatsevtychnyy chasopys. – 2013. – № 4. – S. 63-67.
6. Kalushka O. B. Doslidzhennya infuziynykh rozchyniv na ukrayinsʹkomu farmatsevtychnomu rynku / O. B. Kalushka, A. V. Sokolovsʹka, T. A. Hroshovyy // Farmatsevtychnyy chasopys. – 2015. – № 4. – S. 46-51.
7. Trygubchak O. V. Marketynhovi doslidzhennya rynku shypuchykh tabletok / O. V. Trygubchak // Zdobutky eksperymentalʹnoyi i klinichnoyi medytsyny. – 2014. – № 2 (21). – S. 22-25.
8. Musumba C. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers / C. Musumba, D. M. Pritchard, Et. M. Pirmohamed // Aliment Pharmacol Ther. – 2009. – Vol. 30. – P. 517-531.
9. Hazlewood G. Paracetamol for the management of pain in inflammatory arthritis: a systematic literature review / Glen Hazlewood, M. van der Heijde Désirée, Claire Bombardier // The Journal of Rheumatology. Supplement. – 2012. – Vol. 90. – P. 11-16.
10. NSAIDs vs acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity influencing the outcomes / Verkleij S. P. J., Luijsterburg P. a. J., Bohnen A. M. [et аl.] // Osteoarthritis and cartilage. – 2011. – Vol. 19, Iss. 8. – P. 921-929.
11. Comparative Effectiveness Review. Number 4. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis / [M. D. Roger Chou, M. D. Mark Helfand, M. S. Kim Peterson et аl.] ; Oregon Evidence-basedPracticeCenter. – Rockville, Agency for Healthcare Research and Quality, 2006. – 125 p.
12. Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury / [Peter Jones, Stuart R. Dalziel, Rain Lamdin et аl.] ; The Cochrane Collaboration. – John Wiley & Sons Ltd., 2015. – 127 р.
13. Efficacy of a comprehensive rehabilitation programme combined with pharmacological treatment in reducing pain in a group of OA patients on a waiting list for total joint replacement / Casale Roberto, Damiani Carlo, Rosati Vanessa [et аl.] // Clinical and Experimental Rheumatology. – 2012. – Volume 30, Issue 2. – P. 233-239.
14. Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews / [R. Andrew Moore, Philip J. Wiffen, Sheena Derry et al.] ; The Cochrane Collaboration. – John Wiley & Sons Ltd., 2015. – 32 р.
15. Trygubchak O. V. Trend Analysis of Combined Drugs Creation (for example Acetylsalicylic Acid) / O. V. Trygubchak, L. S. Voytkova // Journal of Pharmacy and Pharmacology. – 2015. – Issue 10, Volume 3, October 2015 (Serial Number 23). – Р. 451-462.
16. Compendium : [Elektronnyy resurs] / http://www.compendium.com.ua/